In her latest op-ed for MM+M, Susan Perlbachs, Chief Creative Officer, delivers a powerful reflection on the FDA’s recent wave of untitled and warning letters—and the broader implications for how pharma is scrutinized compared to other industries.
This article isn’t just a critique—it’s a call to action. Susan explores how life-saving innovations in pharma are often shackled by regulatory constraints that don’t apply to industries with equally profound public health impacts. From fast food to soda, she asks: why does pharma face penalties for emphasizing benefits, while others skate by unchecked?
Life is a constant balancing act of risk versus benefit, yet pharma is asked to play a game with a scale no one else is forced to use. – Susan Perlbachs
Susan’s voice is one of clarity and conviction, reminding us that while pharma must do better, it also deserves a fair playing field.
Read the full article here.